Regenerative Medicine Industrialization Task Force (RMIT)

Regenerative Medicine Industrialization Task Force (RMIT) has been established as a task force under Forum for Innovative Regenerative Medicine (FIRM).

(Objectives)
Japan has set up the most advanced legal and regulatory environment for industrialization of regenerative medicine and cell therapy since the progressive legislations that took place in the autumn of 2014. Encouraged by that, some of the FIRM member companies have volunteered to organize Regenerative Medicine Industrialization Task Force (RMIT) and organized an industrialization support team as its initiating activity. This support team is meant to help wide spectrum of organizations such as established mega pharma, emerging venture businesses, or thriving academia, domestic and overseas alike, resolving various bottlenecks that hinder prompt industrialization of regenerative medicine and cell therapy. Our ultimate goal is to serve patients who crave break-through therapies by accelerating application of the state-of-the-art medical technologies.

(Activities)
With respect to industrialization of regenerative medicine and cell therapy, our support team will provide responses to the following requests and inquiries. Upon necessity, we may connect clients to relevant FIRM member companies for them to collaborate to further tackle the problems.
The services provided by the support team are principally free of charge for the time being.

1) Inquiries on regulatory issues
2) Inquiries on procurement, purchase, or trial use of materials, consumables and/or equipment
3) Inquiries on procurement, purchase, or trial use of apparatuses, machines, and/or facility
4) Inquiries and/or requests relating to manufacture and quality assurance
5) Inquiries relating to clinical studies
6) Inquiries relating to clinical trials
7) Inquiries around application and commercialization of products, e.g., excellent medical clinics for collaboration
8) Requests and/or inquiries with any other aspects concerning industrialization of regenerative medicine and cell therapy

(Access)
E-mail correspondence is encouraged for oversea clients due to the time difference. If you prefer to call us, our lines are open from 0900 to 1200 and 1300 to 1600 Japan Standard Time, Monday through Friday.

E-mail: info-tf@firm.or.jp
Phone: +81 3 3510 9621 (English) +81 3 3510 9620 (Japanese)
Regenerative Medicine Industrialization Task Force (RMIT) established in Forum for Innovative Regenerative Medicine (FIRM) will provide referral and information provision services in order to facilitate commercialization of regenerative medicine (the “Services”).

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, THE SERVICES ARE PROVIDED ON “AS AVAILABLE” AND “WITH ALL FAULTS” BASIS AND PROVIDED WITHOUT WARRANTIES, CONDITIONS, REPRESENTATIONS OR GUARANTEES OF ANY KIND, EITHER EXPRESSED, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, SATISFACTORY QUALITY, CORRECTNESS, COMPLETENESS, NONINFRINGEMENT OF ANY PARTY’S RIGHT OR FITNESS FOR A PARTICULAR PURPOSE. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY RMIT SHALL CREATE A WARRANTY.

After the provision of the Services, RMIT shall not be responsible for any process or result in discussion or negotiation between you and any referred party.